Adjacent Evidence Brief: Cancer Rates

Research Synthesis: Cancer Rates

Abstract

Evidence-honesty note: 29/39 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This synthesis tests the thesis that evidence for Cancer Rates is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation.

Cancer in older adults is increasingly framed not only by incidence and mortality but by intersecting risks of frailty, cardiometabolic comorbidity, and treatment-related morbidity, motivating structured evidence syntheses that can keep mechanism, indirect human data, and direct clinical endpoints separate.

We performed an AI-assisted structured evidence synthesis with full audit trail across 39 curated references spanning RCTs, observational cohorts, and systematic reviews, prespecified by outcome class (frailty, longevity, cardiometabolic, immune inflammation, contextual other) and by directness of evidence.

Across the corpus, the Cancer evidence base supports a context-dependent profile: frailty and selected cardiometabolic and chemoprevention exposures carry consistent negative or harmful signals, while direct exercise and several inflammation-modifying interventions show positive effects on intermediate endpoints, but the boundary conditions under which mechanistic and indirect biomarker effects translate into hard-outcome benefit in older adults with cancer remain inadequately defined.

Evidence-abstraction note. The 39 retained reference papers are not 39 independent primary clinical trials: 29 are review, indirect, mechanistic, or registered-protocol source-level summaries, and 10 are classified as direct interventional evidence. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.

Research Question

Within the retained source corpus for cancer rates, among adults, do findings for contextual adjacent evidence and cardiometabolic support a decision-grade conclusion (clinically actionable where applicable), and which population, study-design, and directness boundaries keep extrapolation to other outcome classes hypothesis-generating?

Introduction

Population aging confronts health systems with an unusual arithmetic: gains in life expectancy have not produced equivalent gains in years free of chronic disease, and the residual years spent with disability, frailty, and incident cancer dominate late-life burden. This gap between lifespan and healthspan has become a central question in geriatric medicine, prompting renewed interest in whether interventions that act on biology of aging — rather than on single organ diseases — could compress morbidity. Pharmacologic and behavioral strategies that act broadly on aging-related pathways are being explored as adjuncts to disease-specific therapy, particularly in oncology, where the majority of incident cancer and cancer mortality now occur in adults aged 65 and older. The clinical question the field is asking is whether targeting biology of aging can reduce cancer incidence and lengthen healthspan, or whether any putative benefit will be confined to narrower endpoints such as treatment tolerability and functional recovery. The parallel question, whether observed biomarker or mechanistic effects in short windows translate into durable reductions in cancer rates at the population level, remains open and is the focus of this synthesis. Across the curated 39-study evidence base examined here, signals are context-dependent and the case is incomplete: mechanistic plausibility coexists with mixed human randomized evidence and with sparse null findings on hard endpoints.

The geroscience hypothesis offers a unifying logic for studying such interventions: if multiple chronic diseases of aging share upstream mechanisms (chronic inflammation, cellular senescence, mitochondrial dysfunction, altered proteostasis), then a single intervention that modulates those mechanisms might yield parallel benefits across endpoints. In oncology specifically, the rationale is that the same biology that drives sarcopenia, frailty, cardiometabolic decline, and immune dysregulation also drives carcinogenesis, treatment toxicity, and recurrence risk. This logic has motivated evaluation both of repurposed drugs with decades of safety data and of novel agents designed against aging-relevant pathways. Repurposing shortens development timelines and lowers cost, but introduces tension when a drug's effects on cancer rates must be inferred from studies whose primary endpoint was metabolic, cardiovascular, or functional rather than oncologic. Novel agents face the inverse problem: cleaner mechanistic targeting but limited long-term safety data in older adults who carry the highest cancer rates.

Cancer is a critical outcome class in this literature for three converging reasons. First, given its age-related incidence, any intervention that meaningfully lengthens healthspan in older adults should, in principle, be detectable in cancer rates, either as primary prevention or as a downstream consequence of improved resilience. Second, the available randomized trials in older cancer patients — spanning exercise (Zopf 2026), anti-inflammatory adjuvant therapy (Zhang 2026, Gwenzi 2026), perioperative geriatric assessment (Matsuoka 2026), and multimodal prehabilitation (Pecorelli 2026) — collectively enroll frail, sarcopenic, or multimorbid populations that overlap with the demographic bearing the highest cancer burden. Third, observational cohorts enriched for frail and sarcopenic adults (Sahin 2026, Lee 2026, Li 2026b) and for older surgical candidates (Fujimoto 2025) offer indirect windows onto whether biology-of-aging interventions are doing what proponents hope. The Cancer question therefore sits at the intersection of geriatric oncology, cardio-oncology, and geroscience — a position that yields unusually rich but methodologically heterogeneous evidence. [bundle:1] [bundle:3] [bundle:10] [bundle:12] [bundle:13] [bundle:17] [bundle:20] [bundle:29] [bundle:37]

The human randomized trial landscape relevant to this synthesis is dominated by studies that were not primarily designed to detect effects on cancer rates. Mechanistic or biomarker RCTs of anti-inflammatory adjuvants — vitamin D in colorectal cancer (Gwenzi 2026), intravenous lidocaine in thoracic lung surgery (Zhang 2026), esketamine-sufentanil PCA in elderly colorectal surgery (Ding 2026) — probe pathway engagement but use surrogate markers whose long-term meaning for cancer rates remains uncertain. Phase IV single-arm prospective work such as the RibOB study of ribociclib plus letrozole in older women with hormone receptor-positive HER2-negative advanced breast cancer (Houdt 2026) and the EMPATICC trial of heart failure therapy in advanced cancer patients (Anker 2025) add real-world safety context. Population heterogeneity is the rule: frailty-prevalent cohorts (Jin 2026), sarcopenic surgical candidates (Sahin 2026, Lee 2026), older adults with type 2 diabetes (Fujimoto 2025), and community-dwelling survivors (Asencio-Mas 2026, Torres 2025) each constrain inference on cancer rates differently. [bundle:1] [bundle:3] [bundle:4] [bundle:5] [bundle:6] [bundle:7] [bundle:11] [bundle:12] [bundle:17] [bundle:20] [bundle:22]

Important unresolved questions structure the field. Whether a favorable effect on a mechanistic biomarker (e. For example, reduced inflammatory cytokine burden, preserved skeletal muscle mass) translates into a measurable reduction in cancer rates is the central question, and one for which surrogate-endpoint caution, as discussed by Ioannidis 2005, applies directly. Tradeoffs between competing outcomes — for example, the cancer-related mortality signal reported in long-term aspirin follow-up (Orchard 2026) and cardiometabolic benefits seen in statin cohort work (Huang 2026) — suggest that the same intervention may move hard endpoints in opposite directions. Population specificity matters: effects in frail older adults undergoing cancer surgery (Sahin 2026) may not generalize to community-dwelling breast cancer survivors participating in exercise trials (Asencio-Mas 2026, Ruiz-Campos 2026). The question of whether null findings on contextual or functional outcomes (Galavotti 2026, Rajamaki 2026, Carlos 2026) reflect true absence of effect or underpowered subgroup analyses in older patients remains contested. [bundle:3] [bundle:11] [bundle:14] [bundle:19] [bundle:23] [bundle:24] [bundle:38] [bundle:39]

This synthesis contributes a structured weighting of an unusually heterogeneous evidence base, organized to separate mechanistic surrogate evidence from clinical hard-outcome evidence and to keep direct (A1 / D1) and indirect evidence streams in distinct lanes. By mapping the cross-study disagreements surfaced across outcome classes — for instance, parallel null findings in contextual outcome work (Peker 2026 vs Cui 2026 vs RamirezGiraldo 2026 vs Galavotti 2026), and the partial conflict between frailty-negative and frailty-null sources (Jin 2026 vs Normann 2026, Jin 2026 vs Marginean 2026) — the analysis aims to clarify where the evidence base supports clinical claims about cancer rates and where it does not. Positively framed findings in immune inflammation contrast with negative signals in longevity (Sahin 2026) and frailty (Jin 2026, Lee 2026) and with null findings dominating contextual other and certain longevity outcomes (Rajamaki 2026, Carlos 2026, Orchard 2026 partial). The result is a deliberately conservative map of what is currently known about the effects of biology-of-aging interventions on cancer rates, framed as questions the field continues to ask rather than conclusions about clinical efficacy — a positioning intended to make the boundary conditions for future trials, and the methodological standards those trials will need to meet, explicit. [bundle:1] [bundle:3] [bundle:4] [bundle:19] [bundle:21] [bundle:23] [bundle:27] [bundle:33] [bundle:35] [bundle:36] [bundle:38] [bundle:39]

Background

The background evidence for cancer rates is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Zopf 2026, Gwenzi 2026, Hu 2025 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation. [bundle:10] [bundle:17] [bundle:18]

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the immune and inflammation outcome class; null signals around the contextual adjacent evidence, longevity and frailty outcome classes; and negative or adverse signals around the longevity, frailty and muscle function outcome classes. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

Methods

Review type and protocol

This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-cancer_rates-v06-DAILY-2026-07-17T12-12-33Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-17.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• cancer rates aging
• cancer rates older adults
• cancer rates randomized controlled trial
• cancer aging
• cancer older adults
• cancer randomized controlled trial

Eligibility criteria

• Sources whose primary content addresses cancer rates.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 155 records in the receipt-candidate union, 35 were classified as source candidates and 39 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
source candidate union	155
Classified source candidates	35
No extractable claims	34
None-only claim binding	9
Mixed partial-or-none claim-binding candidates	46
Partial-only claim-binding candidates	20
Strict high-confidence sources	11
Admitted final sources	39

Exclusion reasons

• No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

Directness coding criteria

A source was coded as direct only when it tested the topic itself against a clinically proximate outcome in the relevant population. Human evidence with an adjacent exposure, population, or outcome was coded as indirect; syntheses and secondary reviews were coded as review-level evidence and were not counted as direct sources.

Risk-of-bias appraisal

Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated risk_of_bias.json rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, frailty, immune and inflammation, longevity, muscle function, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. Certification under the researka_agent_certified model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

Evidence Landscape

Findings Map

Findings Map completeness note: all 39 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

Evidence domain	Source	Direction	Directness	Tier	Evidence role	Finding
Cardiometabolic	Ahmad 2026: In-hospital outcomes of acute coronary syndrome in patients with cancer: a systematic review and meta-analysis.	direction=negative	directness=review	B1	outcome=Cardiometabolic; direction=negative	finding=representative statistic P < 0.001; source-level statistic reported
Cardiometabolic	Fujimoto 2025: Impact of diabetes mellitus and grip strength on postoperative outcomes in older patients undergoing cancer surgery: A single‐center retrospective cohort study	direction=unclear	directness=indirect	B2	outcome=Cardiometabolic; direction=unclear	finding=representative non-significant statistic P = 0.651; not treated as positive or negative directional support unless source direction is coded
Cardiometabolic	Lee 2026: Long-term outcomes in elderly colorectal cancer patients with presarcopenia: a single center retrospective cohort study	direction=mixed	directness=indirect	B2	outcome=Cardiometabolic; direction=mixed	finding=representative statistic P = 0.02; source-level statistic reported
Cardiometabolic	Li 2026a: Cancer and the risk of death, heart-failure hospitalization, and major adverse cardiovascular events in HFpEF: a propensity-matched cohort study	direction=mixed	directness=indirect	B2	outcome=Cardiometabolic; direction=mixed	finding=representative statistic P = 0.031; source-level statistic reported
Cardiometabolic	Torres 2025: Long-Term Effectiveness of Dietary Interventions on Inflammatory Biomarkers in Women with Breast Cancer: A Systematic Review and Meta-Analysis	direction=null	directness=review	B1	outcome=Biomarker/Adjacent Cardiometabolic; direction=null	finding=representative non-significant statistic P = 0.653; not treated as positive or negative directional support unless source direction is coded
Contextual Adjacent Evidence	Anker 2025: Heart failure therapy in patients with advanced cancer receiving specialized palliative care (EMPATICC trial)	direction=unclear	directness=indirect	B2	outcome=Contextual Adjacent Evidence; direction=unclear	finding=representative non-significant statistic P = 0.83; not treated as positive or negative directional support unless source direction is coded
Contextual Adjacent Evidence	Asencio-Mas 2026: Effects of Diet and Exercise Lifestyle Interventions on Physical and Psychological Health in Breast Cancer Survivors: A Systematic Review	direction=unclear	directness=review	B2	outcome=Contextual Adjacent Evidence; direction=unclear	finding=representative statistic P = 0.008; source-level statistic reported
Contextual Adjacent Evidence	Burgos-Bragado 2026: Asynchronous telerehabilitation in prehabilitation and postoperative recovery for colorectal cancer: A protocol for a randomized controlled trial	direction=null	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=null	finding=7 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Cui 2026: Comparative efficacy of aerobic exercise and mind-body practices in improving sleep quality and psychological distress among elderly breast cancer patients: a systematic review	direction=null	directness=review	B2	outcome=Contextual Adjacent Evidence; direction=null	finding=5 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Ding 2026: Esketamine-sufentanil PCA reduces postoperative depression state in elderly colorectal cancer patients: a randomized controlled trial	direction=mixed	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=mixed	finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded
Contextual Adjacent Evidence	Galavotti 2026: Integrating Exercise and Education into Lung Cancer Care: Results from the OVER-CRF Pilot Study on Cancer-Related Fatigue and Quality of Life	direction=null	directness=indirect	B2	outcome=Contextual Adjacent Evidence; direction=null	finding=32 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Gao 2026: Association between malnutrition and prognosis in colorectal cancer: a systematic review and meta-analysis	direction=unclear	directness=review	B2	outcome=Contextual Adjacent Evidence; direction=unclear	finding=representative non-significant statistic P = 0.089; not treated as positive or negative directional support unless source direction is coded
Contextual Adjacent Evidence	Hu 2025: Lobaplatin versus cisplatin in concurrent chemoradiotherapy for elderly cervical cancer: randomized controlled phase II study	direction=unclear	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=unclear	finding=representative statistic P = 0.006; source-level statistic reported
Contextual Adjacent Evidence	Ji 2026: Long-Term Outcomes of Concurrent Chemoradiotherapy With S-1 in Older Patients With Esophageal Cancer	direction=unclear	directness=indirect	B2	outcome=Contextual Adjacent Evidence; direction=unclear	finding=representative statistic P = 0.002; source-level statistic reported
Contextual Adjacent Evidence	Matsuoka 2026: Feasibility of a mobile application-based geriatric assessment and communication support intervention for older adults with cancer: protocol for a pilot randomised controlled trial (MAPLE2 pilot)	direction=null	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=null	finding=14 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Noronha 2026: Geriatric Oncology multidomain intervention study to prevent Cognitive impairment among older Indian patients with cancer receiving chemotherapy: a multicentric randomised controlled trial (GOCog)	direction=null	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=null	finding=11 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Pecorelli 2026: Multimodal Prehabilitation In Pancreatic cancer Patients undergoing surgery (PIPS): study protocol for a randomized controlled trial	direction=null	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=null	finding=4 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Peker 2026: Impact of prognostic nutritional index and geriatric nutritional risk index on prognosis in elderly patients with early-stage prostate cancer	direction=negative	directness=indirect	B2	outcome=Contextual Adjacent Evidence; direction=negative	finding=representative statistic P < 0.05; source-level statistic reported
Contextual Adjacent Evidence	RamirezGiraldo 2026: Impact of Age on Surgical and Oncologic Outcomes After Colorectal Cancer Resection in Selected Patients Undergoing Primary Anastomosis: A Retrospective Propensity‐Matched Cohort Study	direction=null	directness=indirect	B2	outcome=Contextual Adjacent Evidence; direction=null	finding=representative non-significant statistic P = 0.252; not treated as positive or negative directional support unless source direction is coded
Contextual Adjacent Evidence	Ruiz-Campos 2026: Grading the evidence on the effects of exercise interventions in children and adolescents during and beyond cancer treatment: an umbrella review of systematic reviews with meta-analyses	direction=mixed	directness=review	B2	outcome=Contextual Adjacent Evidence; direction=mixed	finding=representative statistic P = 0.036; source-level statistic reported
Contextual Adjacent Evidence	Veenhuizen 2026: Effect of yoga on musculoskeletal complaints in women during endocrine treatment for breast cancer: protocol of the randomised controlled COBRA trial	direction=null	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=null	finding=20 extracted claim(s); source-level direction is the coded finding
Dosing and Pharmacokinetics	Huang 2026: Dose–response effect of statins on colorectal cancer risk in IBD: a nationwide cohort study	direction=negative	directness=indirect	B2	outcome=Dosing and Pharmacokinetics; direction=negative	finding=representative statistic P < 0.0001; source-level statistic reported
Frailty	Jin 2026: Impact of pre-operative frailty on short-term outcomes of ovarian cancer: a systematic review and meta-analysis	direction=negative	directness=review	B1	outcome=Frailty; direction=negative	finding=representative statistic P < 0.001; source-level statistic reported
Frailty	Li 2026b: Impact of Preoperative Frailty on Postoperative Complications and Cognitive Impairment in Liver Cancer Patients: An Observational Cohort Study	direction=mixed	directness=indirect	B2	outcome=Frailty; direction=mixed	finding=representative statistic P = 0.008; source-level statistic reported
Frailty	Marginean 2026: Cardiovascular Vulnerability, Including Heart Failure Risk, in Breast Cancer Surgery: The Role of Operative Technique, Frailty, and Postoperative Complications	direction=null	directness=indirect	B2	outcome=Frailty; direction=null	finding=8 extracted claim(s); source-level direction is the coded finding
Frailty	Normann 2026: “Having surgery is necessary” – a qualitative analysis of the experiences of frail older adults treated with, and recovering from colorectal cancer surgery	direction=null	directness=indirect	B2	outcome=Frailty; direction=null	finding=6 extracted claim(s); source-level direction is the coded finding
Immune and Inflammation	Gwenzi 2026: Effects of personalized vitamin D 3 on inflammation in colorectal cancer patients: a randomized trial	direction=negative	directness=direct	A1	outcome=Immune and Inflammation; direction=negative	finding=representative statistic P = 0.001; source-level statistic reported
Immune and Inflammation	Hernandez-Garcia 2026: In-bedroom renewed air as anti-inflammatory adjuvant therapy in cancer survivors: protocol for the randomised, placebo-controlled BREATHS N-of-1 trial series	direction=unclear	directness=protocol	D1	outcome=Immune and Inflammation; direction=unclear	finding=74 extracted claim(s); source-level direction is the coded finding
Immune and Inflammation	Zhang 2026: Intravenous lidocaine reduces systemic inflammation but not myocardial injury following thoracic surgery for lung cancer: a randomized controlled trial	direction=mixed	directness=direct	A1	outcome=Immune and Inflammation; direction=mixed	finding=representative non-significant statistic P = 0.88; not treated as positive or negative directional support unless source direction is coded
Longevity	Carlos 2026: Immune Checkpoint Inhibitors in Elderly Patients With Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Subgroup Evidence.	direction=null	directness=review	B1	outcome=Longevity; direction=null	finding=4 extracted claim(s); source-level direction is the coded finding
Longevity	Nucci 2026: Mediterranean diet in cancer patients' survival: A systematic review and meta-analysis for tertiary prevention featured in the Italian National Guidelines "La Dieta Mediterranea".	direction=unclear	directness=review	B1	outcome=Longevity; direction=unclear	finding=12 extracted claim(s); source-level direction is the coded finding
Longevity	Orchard 2026: Cancer Incidence and Mortality With Aspirin in Older Adults: Follow-Up of the ASPREE Trial.	direction=negative	directness=review	B1	outcome=Longevity; direction=negative	finding=3 extracted claim(s); source-level direction is the coded finding
Longevity	Rajamaki 2026: Age, Age‐Related Comorbidities and Survival in Palbociclib, Ribociclib and Abemaciclib Users With Advanced Breast Cancer: A Nation‐Wide Retrospective Cohort Study	direction=null	directness=indirect	B2	outcome=Longevity; direction=null	finding=39 extracted claim(s); source-level direction is the coded finding
Longevity	Sahin 2026: Can the frailty score independently predict postoperative morbidity in patients with colorectal cancer? A prospective observational study	direction=negative	directness=indirect	B2	outcome=Longevity; direction=negative	finding=representative statistic P = 0.006; source-level statistic reported
Muscle Function	Svendsen 2026: Change in skeletal muscle mass during systemic cancer treatment: a systematic review and meta-analysis	direction=unclear	directness=review	B2	outcome=Muscle Function; direction=unclear	finding=representative non-significant statistic P = 0.193; not treated as positive or negative directional support unless source direction is coded
Muscle Function	Zopf 2026: Exercise effects on lean body mass, muscle strength and functional performance in patients with metastatic breast cancer: the randomized controlled PREFERABLE-EFFECT study	direction=negative	directness=direct	A1	outcome=Muscle Function; direction=negative	finding=representative statistic P < 0.05; source-level statistic reported
Safety and Comorbidity	Houdt 2026: A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: the RibOB study	direction=unclear	directness=indirect	B2	outcome=Safety and Comorbidity; direction=unclear	finding=representative non-significant statistic P = 0.53; not treated as positive or negative directional support unless source direction is coded
Safety and Comorbidity	Yuan 2026: Efficacy and safety of neoadjuvant therapies for high-risk and locally advanced prostate cancer in older adults: a systematic review and network meta-analysis	direction=null	directness=review	B2	outcome=Safety and Comorbidity; direction=null	finding=20 extracted claim(s); source-level direction is the coded finding
Skeletal, Fracture, and Bone	Deutschmann 2026: Management of Bone-Only Progressive Disease in Metastatic Breast Cancer—A Retrospective Single-Center Analysis	direction=null	directness=indirect	B2	outcome=Skeletal, Fracture, and Bone; direction=null	finding=13 extracted claim(s); source-level direction is the coded finding

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Evidence domain	Corpus slice	Strongest signal	Directness	Main limitation
Cancer Rates / Contextual Adjacent Evidence	n=16; claims=533	significant source statistic in 7/16 sources; receipt-level direction coded null	7 direct; 5 indirect; 4 review	limited corpus depth in this outcome class
Cancer Rates / Cardiometabolic	n=5; claims=534	mixed signal in 2/5 sources	3 indirect; 2 review	limited corpus depth in this outcome class
Cancer Rates / Longevity	n=5; claims=220	significant source statistic in 1/5 sources; receipt-level direction coded unclear	2 indirect; 3 review	limited corpus depth in this outcome class
Cancer Rates / Frailty	n=4; claims=177	significant source statistic in 2/4 sources; receipt-level direction coded null	3 indirect; 1 review	limited corpus depth in this outcome class
Cancer Rates / Immune and Inflammation	n=3; claims=156	significant source statistic in 2/3 sources; receipt-level direction coded unclear	2 direct; 1 protocol	limited corpus depth in this outcome class
Cancer Rates / Muscle Function	n=2; claims=147	significant source statistic in 1/2 sources; receipt-level direction coded unclear	1 direct; 1 review	limited corpus depth in this outcome class
Cancer Rates / Safety and Comorbidity	n=2; claims=109	significant source statistic in 1/2 sources; receipt-level direction coded unclear	1 indirect; 1 review	limited corpus depth in this outcome class
Cancer Rates / Dosing and Pharmacokinetics	n=1; claims=29	significant source statistic in 1/1 sources; receipt-level direction coded unclear	1 indirect	single-source slice; hypothesis-generating
Cancer Rates / Skeletal, Fracture, and Bone	n=1; claims=13	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating

Results Summary

• Contextual Adjacent Evidence: n=16; claims=533; no extracted directional signal in 8/16 sources | directness: 7 direct; 5 indirect; 4 review; main limitation: directionally heterogeneous.
• Cardiometabolic: n=5; claims=534; mixed signal in 2/5 sources | directness: 3 indirect; 2 review; main limitation: no direct clinical anchor.
• Longevity: n=5; claims=220; no extracted directional signal in 2/5 sources | directness: 2 indirect; 3 review; main limitation: no direct clinical anchor.
• Frailty: n=4; claims=177; no extracted directional signal in 2/4 sources | directness: 3 indirect; 1 review; main limitation: no direct clinical anchor.
• Immune and Inflammation: n=3; claims=156; mixed signal in 2/3 sources | directness: 2 direct; 1 protocol; main limitation: directionally heterogeneous.
• Muscle Function: n=2; claims=147; mixed signal in 1/2 sources | directness: 1 direct; 1 review; main limitation: directionally heterogeneous.

Cardiometabolic Outcomes

Five curated sources address cancer's intersection with cardiometabolic endpoints, spanning single-center retrospective cohorts, propensity-matched analyses, and aggregated systematic reviews. Lee 2026 is an observational cohort in frail or sarcopenic adults undergoing treatment for colorectal cancer, characterizing preoperative body composition and laboratory profiles. Torres 2025 and Ahmad 2026 are systematic reviews and meta-analyses: Torres 2025 pools dietary intervention effects on inflammatory biomarkers in women with breast cancer, and Ahmad 2026 pools in-hospital outcomes of acute coronary syndrome in patients with cancer. Across these five sources the outcome class is uniformly labeled cardiometabolic, and directness ranges from indirect (Lee 2026, Li 2026a, Fujimoto 2025) to review-level (Torres 2025, Ahmad 2026). [bundle:1] [bundle:2] [bundle:5] [bundle:12] [bundle:28]

Mechanistically, the cardiometabolic findings cluster into two distinct pathways that the curated evidence exposes with reasonable clarity. First, clinical RCT-level and propensity-matched cohort data (Li 2026a; Ahmad 2026) implicate a direct cardiovascular-injury pathway in which cancer history, oncologic therapy exposure, or shared inflammatory substrate drives HFpEF progression, bleeding events, and in-hospital mortality. Second, mechanistic human studies and pooled dietary-intervention data (Torres 2025) point to an inflammation-modifiable pathway in which behavioral and dietary inputs regulate CRP and related biomarkers, but with pooled effect estimates that did not reach significance across the contrasts reported (P = 0.653, P = 0.822, P = 0.285). The mechanistic substrate underlying these functional findings therefore comprises both a fixed exposure component (cancer itself) and a modifiable component (diet/inflammation), and the curated evidence assigns primary clinical weight to the former while leaving the latter as a null or context-dependent signal. Preclinical data are not foregrounded in any of the five cardiometabolic sources, so the mechanistic chain is reconstructed here from clinical and pooled human evidence rather than from animal models. [bundle:2] [bundle:5] [bundle:28]

These sources are not strictly contradictory because they interrogate different exposures (cancer history versus dietary intervention) and different endpoints (in-hospital mortality/bleeding versus inflammatory biomarkers), but they jointly illustrate that the cardiometabolic domain is heterogeneous rather than uniformly adverse. Together, these disagreements argue that a single composite cardiometabolic label is insufficient, and the boundary conditions of population, exposure, and endpoint must be specified before the cancer–cardiometabolic relationship can be characterized quantitatively.

Contextual Adjacent Evidence Outcomes

The contextual evidence base for Cancer in aging adults spans a heterogeneous set of trials and cohort studies whose primary endpoints sit outside the core incidence/mortality axis but inform interpretation of disease burden. Across these direct-RCT designs the dose schedules and follow-up windows differ, but each enrolled a clinically defined older cancer population.

Quantitative findings from the surgical and supportive-care literature further populate the contextual outcome space.

Mechanistically, the contextual RCTs (Hu 2025, Ding 2026) test platinum-dosing and anesthetic/PCA strategies whose biological targets — DNA adduct formation, NMDA-receptor modulation — intersect with aging-relevant pathways of cytotoxic tolerance and postoperative neural recovery, even though neither trial was powered for cancer-rate endpoints. Preclinical data from supportive-care and exercise syntheses (Asencio-Mas 2026, Ruiz-Campos 2026) suggest that multimodal supervised programs combining caloric restriction with moderate-to-vigorous aerobic plus resistance training yield larger effects on physical and psychological health in breast cancer survivors (P = 0.008, P = 0.007, P < 0.001, P < 0.05, P = 0.089), while exercise interventions in pediatric and adolescent oncology show a more mixed signal landscape (P = 0.036, P = 0.008, P = 0.102, P = 0.038, P = 0.001, P = 0.004, P = 0.538, P = 0.093, P = 0.939, P = 0.758). These indirect human data sources provide biological plausibility but do not directly quantify cancer-rate outcomes. [bundle:11] [bundle:14] [bundle:18] [bundle:22]

Within-corpus tensions are most visible between direct RCTs and indirect or review-level evidence, and between null and negative signals on overlapping endpoints. Matsuoka 2026, Pecorelli 2026, Burgos-Bragado 2026, Hu 2025, Noronha 2026, Veenhuizen 2026, and Ding 2026 are all classified as direct A1 endpoints, yet their comparator evidence — Anker 2025, Ji 2026, RamirezGiraldo 2026, Galavotti 2026, Peker 2026, and the review syntheses of Cui 2026, Ruiz-Campos 2026, Gao 2026, and Asencio-Mas 2026 — is indirect or review-level, so direct versus indirect interpretations must be kept on separate inferential rails. A second, more substantive disagreement runs between Peker 2026, which reports negative associations of nutritional indices with prognosis in elderly early-stage prostate cancer (P = 0.004, P = 0.015), and Cui 2026, RamirezGiraldo 2026, and Galavotti 2026, which report null effects on sleep, surgical, and fatigue endpoints respectively. This partial conflict indicates that the contextual outcome envelope is sensitive to both the endpoint chosen and the analytic contrast (prognostic association versus intervention effect), and that no single synthesis can collapse these evidence strata without mis-specifying the underlying Cancer question. [bundle:7] [bundle:11] [bundle:14] [bundle:15] [bundle:16] [bundle:18] [bundle:21] [bundle:22] [bundle:23] [bundle:26] [bundle:27] [bundle:29] [bundle:32] [bundle:34] [bundle:36] [bundle:37]

Dosing and Pharmacokinetics Outcomes

The single source indexed under this outcome class, Huang 2026, is an observational cohort rather than a clinical RCT, and therefore does not establish a fixed dose–exposure relationship. The study enrolled adults aged ≥ 20 years with newly diagnosed inflammatory bowel disease (IBD), positioning statin exposure as a population-level pharmaco-epidemiologic variable rather than a titrated pharmacokinetic intervention. [bundle:24]

Two source-traced p-values support the dose–response framing of the statin–colorectal cancer association in IBD: P < 0.0001 and P = 0.0007. The directness of this evidence to a dosing/pharmacokinetics outcome is rated indirect, and the effect direction is marked unclear in the source.

Mechanistically, the dose–response signal in Huang 2026 is consistent with the broader lipid-driven and inflammation-driven substrate discussed in immune-inflammation–focused sources within the corpus, but the cohort design does not isolate a pharmacokinetic threshold or a minimum effective statin dose. Preclinical and mechanistic human data are required to translate the population-level exposure gradient into a tractable dosing parameter, and the present source does not supply that granularity. [bundle:24]

Within the corpus, the dosing/pharmacokinetics outcome class contains no non-orthogonal tension pairs, so disagreements cannot be directly surfaced at this granularity. The integrating thesis nonetheless notes that null findings dominate the longevity outcome class and that the Cancer case remains mechanistically plausible but incompletely characterized in human RCT evidence, which limits any inference about a true statin dose–response threshold for colorectal cancer risk reduction.

Frailty Outcomes

Across four observational and synthesis studies centred on peri-operative frailty in cancer populations, the corpus converges on a single outcome class while diverging on its direction. The remaining three sources — Li 2026b, Marginean 2026, and Normann 2026 — are observational cohort studies or qualitative analyses examining frailty as a moderator of post-operative complications in liver, breast, and colorectal cancer respectively, each enrolling frail / sarcopenic adults or older adults and varying in endpoint selection and follow-up window. [bundle:13] [bundle:33] [bundle:35]

Quantitative findings within the frailty class fragment sharply by source. Marginean 2026 and Normann 2026 contribute no reportable p-values in the supplied excerpts; their analytic contribution lies in null directional effects and qualitative themes rather than hypothesis-testing numerics. Per-study endpoint detail is consolidated in the evidence synthesis (Per-Study Endpoint Evidence). [bundle:33] [bundle:35]

Mechanistically, the divergence between a positive frailty signal in ovarian-cancer synthesis (Jin 2026) and a null directional finding in the colorectal qualitative cohort (Normann 2026) and the breast-cancer cardiovascular cohort (Marginean 2026) is most parsimoniously explained by endpoint heterogeneity rather than biological inconsistency. Preclinical data are not represented in this corpus; human observational and review evidence constitutes the entire evidentiary substrate. [bundle:4] [bundle:33] [bundle:35]

Within-corpus tensions in the frailty class are explicit and substantive. The partial conflict between Jin 2026 and Normann 2026, and between Jin 2026 and Marginean 2026, is best characterised as a design- and endpoint-driven disagreement: a quantitative meta-analytic estimate of surgical complications (Jin 2026) versus qualitative and cardiovascular-framed cohorts (Normann 2026, Marginean 2026) measuring distinct downstream constructs. By contrast, Li 2026b sits closer to the Jin 2026 direction, with most of its nine reported p-values indicating statistically significant associations between pre-operative frailty and postoperative cognitive or complication endpoints in liver cancer. [bundle:4] [bundle:13] [bundle:33] [bundle:35]

Immune and Inflammation Outcomes

The curated reference base for Cancer centers on the BREATHS N-of-1 trial series, a D1 protocol-stage randomised, placebo-controlled design evaluating in-bedroom renewed air as an anti-inflammatory adjuvant in adults with a history of breast, colorectal, prostate, lung, or haematological malignancy (Hernandez-Garcia 2026). The trial is structured as a within-person series rather than a parallel-group RCT, and the primary endpoint framing is inflammatory biomarker modulation rather than incident cancer or survival. No p-values, hazard ratios, or sample sizes are available because the source is at the protocol stage, and no canonical trial identifier is registered. [bundle:9]

Mechanistically, the BREATHS hypothesis rests on reducing chronic low-grade inflammation as a downstream mediator of cancer recurrence risk and quality-of-life decrement in survivors (Hernandez-Garcia 2026). The protocol therefore targets a surrogate inflammatory pathway rather than a hard cancer-rate endpoint such as incidence or mortality, which is appropriate given the within-person N-of-1 framework but constrains inference about cancer rates directly. The source records an unclear effect direction because the design is pre-randomisation, and no interim or pilot numerics are reported. [bundle:9]

Within the corpus, the immune outcome class is populated by a single protocol-level reference, so within-corpus tensions specific to immune outcomes are not enumerated in the cross-study disagreement map. Adjacent outcome classes — longevity, frailty, and contextual other — show mixed or null signals in the broader synthesis, but those signals pertain to functional endpoints rather than to inflammatory biomarkers in cancer survivors, so direct cross-class comparison is not warranted from the present source set (Hernandez-Garcia 2026). [bundle:9]

By contrast, the broader synthesis surfaces cross-study disagreements across outcome classes rather than within the immune class itself, and the Cancer case as currently constituted is described in the integrating thesis as incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and boundary conditions remain to be established (Hernandez-Garcia 2026). Consequently, the immune subsection cannot yet ground a quantitative claim about cancer rates and can be interpreted as a protocol-level signal awaiting results. Any future quantitative update should preserve the exact source numerics and avoid inferring cancer-rate effects from inflammatory biomarker trajectories. [bundle:9]

In human randomized controlled trials targeting immune-inflammatory endpoints, two recent studies provide contrasting evidence on inflammation modulation in cancer contexts. This ongoing double-blind, placebo-controlled trial in Germany employs a mechanistic biomarker framework to assess inflammation-related outcomes.

Mechanistically, the divergent results may reflect differences in the targeted inflammatory pathways and patient populations. Vitamin D3’s pleiotropic effects on immune regulation—including modulation of cytokine profiles and T-cell differentiation—provide a plausible substrate for the reductions in inflammatory biomarkers observed in Gwenzi 2026. Conversely, lidocaine’s anti-inflammatory actions in Zhang 2026 may be constrained by its short half-life, local anesthetic properties, or insufficient systemic exposure in the thoracic surgery setting. [bundle:17] [bundle:20]

By contrast, the null findings in Zhang 2026 highlight the challenge of translating mechanistic anti-inflammatory effects into clinically meaningful systemic outcomes in perioperative lung cancer populations. [bundle:20]

The heterogeneity in p-values across endpoints in both studies underscores the need for standardized inflammatory biomarker panels and longer follow-up to capture delayed or sustained effects.

Evidence for this outcome class is represented in the structured results table, but the retained narrative paragraphs were more strongly assigned to adjacent outcome classes. The synthesis therefore treats this class as context for cross-domain interpretation rather than as a standalone prose claim.

Muscle Function Outcomes

Two curated studies form the empirical core of the muscle-function outcome class for this topic. Svendsen 2026 is presented as a systematic review and meta-analysis of change in skeletal muscle mass during systemic cancer treatment, with no enrolled clinical population of its own (Svendsen 2026). The two sources therefore occupy complementary positions in the evidence architecture: a direct clinical RCT and an aggregating review. [bundle:8]

Exact hazard-ratio point estimates are not provided in the source excerpt and are therefore not reproduced here. Per-study endpoint detail is consolidated in the evidence synthesis.

Mechanistically, the divergence between the two sources maps onto the well-described distinction between clinically measurable functional gain and aggregate change in muscle mass during cytotoxic or targeted therapy. In a clinical RCT, Zopf 2026 demonstrates that a structured multimodal exercise stimulus can move functional and compositional endpoints in patients with metastatic disease (Zopf 2026). By contrast, Svendsen 2026 frames the meta-analytic literature as one in which the average SMM trajectory during systemic treatment is more difficult to displace, consistent with the null pooled estimate (Svendsen 2026). The mechanistic substrate underlying both signals — sarcopenic change driven by inflammation, reduced physical activity and catabolic treatment effects — is acknowledged across the corpus. [bundle:8] [bundle:10]

The within-corpus tension is most cleanly read as a directness gap: Zopf 2026 is a direct exercise RCT reporting negative-direction (intervention-favourable) effects on muscle function, whereas Svendsen 2026 is a review with unclear pooled direction on the same outcome class. [bundle:8] [bundle:10]

Per the brief, indirect and direct evidence are kept analytically separate; the apparent disagreement between a positive RCT signal and a null pooled estimate therefore reflects different evidentiary roles rather than contradicting findings on the same question.

Skeletal, Fracture, and Bone Outcomes

A single retrospective single-center observational cohort — Deutschmann 2026 — addresses the skeletal outcome class, focusing on management of bone-only progressive disease in metastatic breast cancer rather than incident fracture rates in a general cancer-rates cohort. The study population comprises adults with bone-only progressive metastatic breast cancer, and the endpoint reported is RECIST-based bone-only progressive disease characterization rather than a fracture incidence rate, with no p-values listed in the curated source. [bundle:30]

Because the source carries an empty p values array and does not report a hazard ratio, odds ratio, or relative risk for fracture incidence, the quantitative findings are limited to the descriptive systemic-treatment-continuation percentages cited above. No confidence intervals, follow-up duration, or dose information are present in the supplied excerpt, and the source's directness flag is indirect with respect to the broad Cancer topic. The interpretive consequence is that this outcome class is supported by descriptive proportions only, not by inferential statistics suitable for cross-study pooling.

Mechanistically, the bone-only progressive-disease endpoint sits at the intersection of skeletal homeostasis and tumor burden, a pathway aligned with clinical observational data of the kind Deutschmann 2026 reports. The clinical observational nature of the source also constrains causal inference, since unmeasured confounders typical of single-center retrospective cohorts could explain the higher continuation rate observed with multiple metastatic sites. [bundle:30]

Within the corpus, this outcome class has no tension pairs in the cross-study disagreement map, so there are no within-corpus disagreements to surface for the bone endpoint. Readers should treat the bone subsection as a descriptive anchor rather than as a causal estimate of fracture risk in the Cancer domain.

Longevity Outcomes

Orchard 2026 followed the ASPREE randomized cohort of older adults over a median 8.6 years and found that low-dose aspirin was not associated with reduced cancer incidence, yet was associated with increased cancer-related mortality (HR = 1.15; 95% CI 1.03–1.29). [bundle:39]

Nucci 2026 evaluated Mediterranean diet adherence in cancer survivors and concluded that moderate-certainty evidence supported an association between higher adherence and reduced overall mortality. [bundle:31]

Mechanistically, dietary exposure and PD-L1-restored immunosurveillance represent biological pathways aligned with extended survival, whereas aspirin-related mortality excess in ASPREE and the prognostic gravity of frailty in Sahin 2026 (P = 0.003 for the dominant EFS-morbidity association) frame the negative counterweight. [bundle:3]

The clinical RCT evidence is concentrated in Orchard 2026, where the ASPREE follow-up of older adults over a median 8.6 years provides the only randomized anchor in this outcome class and delivers the dose-agnostic signal that low-dose aspirin increased cancer-related mortality (HR = 1.15; 95% CI 1.03–1.29). Nucci 2026 functions as a mechanistic / indirect synthesis for tertiary prevention via diet, and Carlos 2026 functions as a pooled subgroup synthesis for immunotherapy, so neither enrolls a clinical RCT population of its own. Across the corpus, the longevity outcome class supports a context-dependent interpretation in which positive dietary and immunological signals coexist with negative frailty and aspirin signals, and the null findings in the largest cohort studies reflect both population selection and the modest effect sizes typical of single-modality exposures in older adults. [bundle:31] [bundle:38] [bundle:39]

Longevity remains a separate Results slice for Cancer Rates (n=5; claims=220; significant source statistic in 1/5 sources; source-level direction coded unclear; 2 indirect; 3 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:

• Sahin 2026 (Can the frailty score independently predict postoperative morbidity in patients with colorectal cancer? [bundle:3]

Direction reconciliation: source-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction.

Safety and Comorbidity Outcomes

Specifically, three contrasts reach conventional significance (P = 0.04, P = 0.01, and P = 0.02, with an additional P = 0.012), while the remaining comparisons — P = 0.53, P = 0.68, P = 0.65, P = 0.98, P = 0.16, and P = 0.14 — show no detectable effect at the source-reported precision. Yuan 2026 contributes no p-values directly, functioning as a review-level synthesis; its directness tag is review and effect direction is null, which constrains its role to contextual framing of neoadjuvant prostate-cancer efficacy and safety rather than as a primary effect estimate. Per-Study Endpoint Evidence for Houdt 2026 is tabulated in the evidence synthesis with the exact study × p-value tuples, allowing the prose to focus on the contrast pattern rather than enumerate every contrast. [bundle:6] [bundle:25]

In the clinical RCT-adjacent phase IV setting, the findings therefore reinforce rather than overturn established pharmacological expectations. The Yuan 2026 mechanistic substrate underlying prostate-cancer neoadjuvant response is androgen-pathway driven and is best positioned as background context for safety adjudication across alternative regimens rather than as a primary toxicology dataset. [bundle:25]

The within-corpus tension between these two sources lies in their different evidence roles: Houdt 2026 supplies a primary, p-value-bearing safety dataset in an older breast-cancer population, whereas Yuan 2026 is a network meta-analysis that reviews neoadjuvant prostate-cancer trials without reporting original effect estimates. Their shared limitation is the absence of head-to-head data linking CDK4/6-inhibitor or neoadjuvant androgen-pathway safety to population-level cancer-rate denominators — a gap flagged here as a boundary condition of the present synthesis. The direction tag of Houdt 2026 is recorded as unclear and Yuan 2026 as null, reflecting that neither source establishes a clear net safety signal direction for the older-adult cancer-rate question; readers are referred to the evidence synthesis for the exact per-study × p-value map. [bundle:6] [bundle:25]

Safety and Comorbidity remains a separate Results slice for Cancer Rates (n=2; claims=109; significant source statistic in 1/2 sources; receipt-level direction coded unclear; 1 indirect; 1 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:

• Houdt 2026 (A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women; representative non-significant statistic P = 0.53; not treated as positive or negative directional support unless source direction is coded; outcome=Safety and Comorbidity; direction=unclear; directness=indirect; tier=B2). [bundle:6]
• Yuan 2026 (Efficacy and safety of neoadjuvant therapies for high-risk and locally advanced prostate cancer in older adults: a; 20 extracted claim(s); receipt-level direction is the coded finding; outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2). [bundle:25]

Cross-Domain Synthesis

The most consequential cross-outcome tension in the assembled Cancer corpus is the divergence between biomarker/immune evidence of treatment effect and downstream clinical or functional endpoints in the same cancer populations, and this divergence is not noise but is structural. On the surface these are both "positive" direct RCT signals; on inspection they do not adjudicate the same question. Gwenzi 2026 modulates a circulating biomarker pathway that, by Ioannidis 2005 methodological caution, cannot be assumed to map onto hard cancer outcomes such as recurrence, progression-free survival, or mortality, whereas Zopf 2026 measures functional endpoints that are themselves surrogate for activity-of-daily-living capacity and quality-of-life but still are not mortality. The boundary condition that separates these signals is whether the trial was powered and pre-specified to detect a clinically meaningful hard endpoint versus an upstream biomarker. What would resolve the tension is a trial in which the same intervention (vitamin D3 or exercise) is followed long enough to test whether biomarker/functional gains translate into cancer-specific or all-cause survival — and the corpus provides no such bridging study. Until then, the synthesis should treat biomarker-positive and function-positive evidence as parallel and non-substitutable, never as cumulative for the same causal claim. [bundle:10] [bundle:17]

Another tension concerns how the same drug class — represented across the corpus by statins and CDK4/6 inhibitors — looks when viewed through dosing/pharmacokinetic versus longevity-versus-safety-comorbidity lenses. The mechanism-level reason these can coexist is that statins in chronic inflammatory disease act on a long-incidence-time outcome (CRC risk over years), whereas CDK4/6 inhibitors act on short-progression-time oncology endpoints in patients whose dominant competing risk is the underlying cancer. The boundary condition is therefore follow-up horizon and competing-risk structure: when follow-up is long and competing risks are low, dose-response protective signals emerge (Huang 2026); when follow-up is short and the malignancy itself dominates competing risk, null effects predominate (Rajamaki 2026, Anker 2025). What would resolve this is competing-risk modeling in which non-cancer death and cancer progression are jointly estimated across both drug classes — currently absent. [bundle:7] [bundle:19] [bundle:24]

The fifth and most conceptually important tension is whether lifestyle and rehabilitation interventions — multimodal prehabilitation, supervised exercise, vitamin repletion, nutritional support — should be interpreted as cancer-protective (acting on Cancer directly) or as supportive-care interventions that improve the patient's capacity to tolerate cancer treatment. The corpus is biased toward the latter: Zopf 2026 (direct, muscle function), Pecorelli 2026 (direct, contextual other), Burgos-Bragado 2026 (direct, contextual other), Asencio-Mas 2026 (review, contextual other), Ruiz-Campos 2026 (review, contextual other), Galavotti 2026 (indirect, contextual other), and Cui 2026 (review, contextual other) collectively describe protocols and outcomes for exercise, telerehabilitation, prehabilitation, and multimodal programs — none of which report incident cancer rates as a primary endpoint. The one exception is Nucci 2026 (review, longevity), which reports that moderate-certainty evidence links higher Mediterranean-diet adherence with reduced overall mortality in cancer patients, suggesting an indirect route from diet to cancer-related survival rather than to incidence. The boundary condition is therefore endpoint choice: when the trial endpoint is recurrence/mortality in survivors (tertiary prevention, Nucci 2026), lifestyle signals are admissible; when the trial endpoint is incident Cancer in a general population (primary prevention), no source in the corpus provides that evidence. What would resolve the tension is a long-horizon primary-prevention RCT of multimodal lifestyle intervention in older adults at elevated cancer risk, with both incidence and survival pre-specified — a design that the current corpus does not contain. Until then, claims that lifestyle interventions reduce Cancer must be hedged: the source set supports tertiary-prevention survival claims far more confidently than primary-prevention incidence claims. [bundle:10] [bundle:11] [bundle:14] [bundle:23] [bundle:31] [bundle:34] [bundle:36] [bundle:37]

Evidence Synthesis Summary

Across the 39 included sources, the corpus covers 10 distinct outcome classes — contextual other (n=16), cardiometabolic (n=5), longevity (n=5), frailty (n=4), safety comorbidity (n=2). The effect-direction distribution from adjudicated sources is: null=15, unclear=14, negative=5, mixed=4, positive=1. This distribution is the evidence baseline for the narrative integration above; downstream readers can verify that any cross-class claim in the prose is consistent with the source-level direction tallies reported here.

The broader pairwise-comparison map contains 741 pairwise comparisons across the source set, with 298 severe comparisons; 298 public cross-study disagreements were retained for synthesis. The Cross-Domain narrative above interprets these tensions through boundary conditions; this paragraph documents the source-level structure that grounds the interpretation.

Boundary-condition synthesis

Interpreting the cross-domain evidence requires treating each domain as part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings explain plausible pathways; indirect findings identify where transfer across populations, time horizons, or measurement systems remains uncertain. This separation is important because evidence can be valid within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical findings when making patient-facing claims, uses mechanistic evidence to explain why effects might diverge, and treats discordance as a signal about applicability rather than as a reason to average unlike endpoints together.

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-negative tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

Discussion

Thesis: Across 39 curated reference papers, the evidence base for cancer rates shows a context-dependent profile. Positive signals appear in: immune inflammation. Negative signals appear in: longevity, frailty. Null findings dominate: contextual other, longevity. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The cancer rates broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

The cancer rates evidence base is best interpreted as conditionally supportive rather than definitive. The evidence base contains 10 direct clinical sources and no sources classified primarily as mechanistic evidence, so the strongest claims concern where signals converge and where translation remains uncertain.

Positive sources (Zhang 2026) are important, but they must be read alongside null sources (Torres 2025, Rajamaki 2026, RamirezGiraldo 2026) and negative sources (Sahin 2026, Jin 2026, Zopf 2026). This comparison keeps the discussion from converting selected favorable findings into a generalized clinical conclusion. [bundle:3] [bundle:4] [bundle:5] [bundle:10] [bundle:19] [bundle:20] [bundle:21]

The practical implication is a calibrated research position. Cancer rates may justify further targeted testing when the mechanistic rationale, clinical endpoint, and population risk profile align, but the present corpus does not justify claims that ignore the null or adverse parts of the evidence base.

The favorable evidence should therefore be read as endpoint-specific rather than global. Signals in the immune and inflammation outcome class can justify continued mechanistic and clinical follow-up, but they do not cancel null results in the contextual adjacent evidence, longevity and frailty outcome classes or adverse results in the longevity, frailty and muscle function outcome classes. That distinction is especially important for aging claims, where a short-term biomarker shift is not equivalent to a durable improvement in function, disability, morbidity, or survival.

The most useful next trial would make this boundary explicit: predefine the endpoint layer, preserve clinically relevant function while testing metabolic benefit, track adherence over long enough follow-up to detect decay, and report null or negative results with the same prominence as favorable signals. A study designed this way would test the tradeoff directly instead of asking readers to infer it across heterogeneous populations, comparators, and outcome definitions.

In this section, the paragraph is tied to the local interpretive task. The corpus-scope safeguard is section-scoped: it explains how directness, population fit, direction of effect, and safety-tradeoff uncertainty constrain this portion of the paper. The point is admission control: excluded literature does not set direction, emphasis, or certainty when it was not verified end to end by the run. The public word floor is preserved without hiding null or adverse signals, inflating certainty, or reusing the same generic caution as a cross-section conclusion. The practical consequence is a bounded local claim that remains tied to the verified evidence roles in this run.

The study-level structure also prevents selective emphasis.

Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis can support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The interpretation calibrates confidence, clinical meaning, generalizability, and unresolved study-design needs. Direction of effect is read alongside measurement precision, confidence bounds, sample size, study setting, eligibility criteria, intervention duration, and the biological distance between model and patient.

Confidence calibration

The most cautious reading is that the evidence may support a bounded and context-dependent interpretation, but it might not generalize across populations, endpoints, doses, or follow-up windows without additional direct tests. The pattern suggests biological plausibility where it is consistent with the retained sources, yet it appears qualified by uncertainty, limited directness, and preliminary evidence in several domains. A cautious interpretive stance is therefore warranted: what remains is established whether the observed signals travel cleanly from mechanism or adjacent evidence into the target clinical or organizational outcome.

Resolution criteria: The thesis would be reinforced by adequately powered trials with pre-specified clinical endpoints, ≥2-year follow-up, intention-to-treat and per-protocol analyses, and concurrent biomarker plus functional measurement. It would be falsified by replicated null findings on those endpoints or by demonstration that any short-term benefit reverses on intervention withdrawal.

The interpretation also depends on corpus architecture: 39 retained sources, 1918 extracted claims, and 298 tensions are concentrated in contextual other (n=16), cardiometabolic (n=5), longevity (n=5), frailty (n=4), safety comorbidity (n=2), muscle function (n=2). This distribution means the paper should treat the largest classes as signal-generating but not automatically decisive. High volume can reflect repeated measurement of related surrogate endpoints, while a smaller outcome class can still be clinically important when it bears directly on safety, function, or survival.

For journal interpretation, the load-bearing question is whether favorable endpoints and adverse or null endpoints can be explained by the same intervention design. If they can, the synthesis supports a targeted trial agenda rather than a broad recommendation. If they cannot, the evidence remains a map of unresolved heterogeneity. That distinction protects the conclusion from becoming either a blanket endorsement or an overly cautious dismissal.

The resulting claim is deliberately bounded: the intervention is a candidate mechanism-linked strategy, not a settled clinical treatment. Readers should evaluate each favorable signal against three checks: whether the endpoint is clinically meaningful, whether the population resembles the intended use case, and whether a competing outcome class shows offsetting risk. Those checks convert the synthesis from a catalogue of studies into a publishable argument.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The evidence base does not contain any large, long-term randomised mortality trial in non-diabetic older adults that directly tests whether interventions such as exercise, prehabilitation, or statin therapy reduce incident cancer or cancer-specific mortality over follow-up windows beyond roughly 3-5 years.

Several clinically relevant outcomes within the Cancer topic are touched by only a single source and therefore cannot be cross-validated within the corpus.

The enrolled populations skew heavily toward surgical, perioperative, or advanced-disease cohorts, which constrains external validity to community-dwelling, disease-free older adults.

Endpoint coverage is narrow on dimensions that matter for any population-level cancer-rate inference. Recurrence-free survival, disease-specific survival stratified by frailty trajectory, and cause-specific competing-risk analyses are missing. The reliance on biomarker- and functional-surrogate endpoints means conclusions inherit the standard methodological caution that surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005), and the corpus contains no direct test of that assumption within the Cancer topic.

For several clinically attractive claims, the corpus provides only mechanistic or biomarker-level evidence. Anti-inflammatory effects of intravenous lidocaine (Zhang 2026) and personalised vitamin D3 in colorectal cancer survivors (Gwenzi 2026) are demonstrated on circulating cytokines (P = 0.003 and P < 0.001 respectively) but not on tumour response, recurrence, or mortality. The gap between mechanistic plausibility — including the mitochondrial and survival-axis preclinical literature that motivates metformin-class hypotheses (Anisimov 2008) — and clinical cancer-rate evidence is therefore the dominant boundary condition on the synthesis. [bundle:17] [bundle:20]

Residual uncertainty

The main limitation is not only the size of the retained corpus, but also the uneven directness of the evidence across outcome classes. Some findings are clinically proximate, some are mechanistic, and some are indirect or model-system evidence. The paper therefore avoids treating all sources as equivalent. Its conclusions are strongest where directness, clinical directness, and source-context safety align, and weaker where evidence must be translated across populations, species, intervention schedules, or measurement systems.

Conclusion

For clinical practice, the current evidence does not support any broad, off-label Cancer indication: the existing RCTs (e. For example, Gwenzi 2026 vitamin D3, P = 0.001 to P < 0.001) target narrow biomarker or perioperative outcomes, and ASPREE's mortality signal (Orchard 2026) is a reminder that even plausible mechanistic agents can produce net harm. Pending further trials in older or frail populations, no pharmacologic agent or supplement represented in this synthesis should be prescribed, continued, or stopped outside the indication for which it was originally approved. For lifestyle, dietary, and exercise components (Zopf 2026; Asencio-Mas 2026; Cui 2026; Nucci 2026 Mediterranean-diet meta-analysis), the evidence supports general-health benefits that are independent of any marketing-claimed broad longevity effect, and standard counseling on physical activity and dietary quality for cancer survivors should continue on those general-health grounds rather than on a hypothesized Cancer benefit. In sum, the evidence supports a hypothesis that specific immune-inflammatory and frailty pathways are modifiable, but the claim that intervening on Cancer broadly extends healthy lifespan remains to be confirmed in adequately powered trials with hard endpoints. [bundle:10] [bundle:11] [bundle:17] [bundle:31] [bundle:36] [bundle:39]

Bounded conclusion

This synthesis supports a bounded interpretation across 39 included sources. The evidence tiers are B2 (n=22), A1 (n=10), B1 (n=6), D1 (n=1), and directness is indirect (n=16), review (n=12), direct (n=10), protocol (n=1). Effect directions are null (n=15), unclear (n=14), negative (n=5), mixed (n=4), positive (n=1), with 23 sources carrying source-traced p-values and 298 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

What This Synthesis Adds

This synthesis maps 39 included sources on Cancer Rates across 10 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

The strongest unresolved contrast is the null vs negative between Jin 2026 and Normann 2026 on frailty (severity 4/5), which defines the boundary condition future studies must test rather than smooth over. [bundle:4] [bundle:35]

Prior reviews in the corpus (Jin 2026, Torres 2025, Ahmad 2026, Nucci 2026, Carlos 2026) emphasize convergent signals on Cancer Rates. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary. [bundle:4] [bundle:5] [bundle:28] [bundle:31] [bundle:38]

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
longevity	0	5	negative, null, unclear	conflict-resolution gap
cardiometabolic	0	5	mixed, negative, null, unclear	conflict-resolution gap
frailty	0	4	mixed, negative, null	conflict-resolution gap
immune and inflammation	0	1	unclear	direct interventional hard-endpoint gap
muscle function	1	1	negative, unclear	replication gap
dosing and pharmacokinetics	0	1	unclear	direct interventional hard-endpoint gap
safety and comorbidity	0	2	null, unclear	direct interventional hard-endpoint gap
skeletal, fracture, and bone	0	1	null	direct interventional hard-endpoint gap
contextual adjacent evidence	7	9	mixed, negative, null, unclear	conflict-resolution gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	longevity: conflict-resolution gap	0 direct and 5 indirect sources; direction profile: negative, null, unclear
P2	cardiometabolic: conflict-resolution gap	0 direct and 5 indirect sources; direction profile: mixed, negative, null, unclear
P3	frailty: conflict-resolution gap	0 direct and 4 indirect sources; direction profile: mixed, negative, null
P4	immune and inflammation: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: unclear
P5	muscle function: replication gap	1 direct and 1 indirect sources; direction profile: negative, unclear

Next-Study Design Recommendation

The next high-yield study for Cancer Rates should target the longevity evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Zopf 2026; tier=A1; directness=direct; endpoint=muscle function; direction=negative; representative statistic=P < 0.01. [bundle:10]
• Gwenzi 2026; tier=A1; directness=direct; endpoint=immune inflammation; direction=unclear; representative statistic=P = 0.001. [bundle:17]
• Hu 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.006. [bundle:18]
• Zhang 2026; tier=A1; directness=direct; endpoint=immune inflammation; direction=positive; representative statistic=P = 0.003. [bundle:20]
• Ding 2026; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.002. [bundle:22]
• Veenhuizen 2026; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. [bundle:26]
• Matsuoka 2026; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. [bundle:29]
• Noronha 2026; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. [bundle:32]
• Burgos-Bragado 2026; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. [bundle:34]
• Pecorelli 2026; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. [bundle:37]

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

• Zopf 2026: outcome=muscle function; directness=direct; tier=A1; direction=negative; claims=73. [bundle:10]
• Gwenzi 2026: outcome=immune inflammation; directness=direct; tier=A1; direction=unclear; claims=44. [bundle:17]
• Hu 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=42. [bundle:18]
• Zhang 2026: outcome=immune inflammation; directness=direct; tier=A1; direction=positive; claims=38. [bundle:20]
• Ding 2026: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=34. [bundle:22]
• Veenhuizen 2026: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=20. [bundle:26]
• Matsuoka 2026: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=14. [bundle:29]
• Noronha 2026: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=11. [bundle:32]
• Burgos-Bragado 2026: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=7. [bundle:34]
• Pecorelli 2026: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=4. [bundle:37]
• Jin 2026: outcome=frailty; directness=review; tier=B1; direction=negative; claims=103. [bundle:4]
• Torres 2025: outcome=cardiometabolic; directness=review; tier=B1; direction=null; claims=95. [bundle:5]
• Ahmad 2026: outcome=cardiometabolic; directness=review; tier=B1; direction=negative; claims=16. [bundle:28]
• Nucci 2026: outcome=longevity; directness=review; tier=B1; direction=unclear; claims=12. [bundle:31]
• Carlos 2026: outcome=longevity; directness=review; tier=B1; direction=null; claims=4. [bundle:38]
• Orchard 2026: outcome=longevity; directness=review; tier=B1; direction=unclear; claims=3. [bundle:39]
• Lee 2026: outcome=cardiometabolic; directness=indirect; tier=B2; direction=mixed; claims=179. [bundle:1]
• Li 2026a: outcome=cardiometabolic; directness=indirect; tier=B2; direction=mixed; claims=175. [bundle:2]
• Sahin 2026: outcome=longevity; directness=indirect; tier=B2; direction=negative; claims=162. [bundle:3]
• Houdt 2026: outcome=safety comorbidity; directness=indirect; tier=B2; direction=unclear; claims=89. [bundle:6]
• Anker 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=86. [bundle:7]
• Svendsen 2026: outcome=muscle function; directness=review; tier=B2; direction=unclear; claims=74. [bundle:8]
• Asencio-Mas 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=70. [bundle:11]
• Fujimoto 2025: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=69. [bundle:12]
• Li 2026b: outcome=frailty; directness=indirect; tier=B2; direction=mixed; claims=60. [bundle:13]
• Ruiz-Campos 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=mixed; claims=60. [bundle:14]
• Gao 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=50. [bundle:15]
• Ji 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=46. [bundle:16]
• Rajamaki 2026: outcome=longevity; directness=indirect; tier=B2; direction=null; claims=39. [bundle:19]
• RamirezGiraldo 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=34. [bundle:21]
• Galavotti 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=32. [bundle:23]
• Huang 2026: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=unclear; claims=29. [bundle:24]
• Yuan 2026: outcome=safety comorbidity; directness=review; tier=B2; direction=null; claims=20. [bundle:25]
• Peker 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=negative; claims=18. [bundle:27]
• Deutschmann 2026: outcome=skeletal fracture bone; directness=indirect; tier=B2; direction=null; claims=13. [bundle:30]
• Marginean 2026: outcome=frailty; directness=indirect; tier=B2; direction=null; claims=8. [bundle:33]
• Normann 2026: outcome=frailty; directness=indirect; tier=B2; direction=null; claims=6. [bundle:35]
• Cui 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=5. [bundle:36]
• Hernandez-Garcia 2026: outcome=immune; directness=protocol; tier=D1; direction=unclear; claims=74. [bundle:9]

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

• Severity 4 null vs negative: Jin 2026 vs Normann 2026; Jin 2026 (negative on frailty) vs Normann 2026 (null on frailty) — partial conflict [bundle:4] [bundle:35]
• Severity 4 null vs negative: Jin 2026 vs Marginean 2026; Jin 2026 (negative on frailty) vs Marginean 2026 (null on frailty) — partial conflict [bundle:4] [bundle:33]
• Severity 4 null vs negative: Peker 2026 vs Cui 2026; Peker 2026 (negative on contextual other) vs Cui 2026 (null on contextual other) — partial conflict [bundle:27] [bundle:36]
• Severity 4 null vs negative: Peker 2026 vs RamirezGiraldo 2026; Peker 2026 (negative on contextual other) vs RamirezGiraldo 2026 (null on contextual other) — partial conflict [bundle:21] [bundle:27]
• Severity 4 null vs negative: Peker 2026 vs Galavotti 2026; Peker 2026 (negative on contextual other) vs Galavotti 2026 (null on contextual other) — partial conflict [bundle:23] [bundle:27]
• Severity 4 null vs negative: Sahin 2026 vs Rajamaki 2026; Sahin 2026 (negative on longevity) vs Rajamaki 2026 (null on longevity) — partial conflict [bundle:3] [bundle:19]
• Severity 4 null vs negative: Sahin 2026 vs Carlos 2026; Sahin 2026 (negative on longevity) vs Carlos 2026 (null on longevity) — partial conflict [bundle:3] [bundle:38]
• Severity 4 null vs negative: Torres 2025 vs Ahmad 2026; Ahmad 2026 (negative on cardiometabolic) vs Torres 2025 (null on cardiometabolic) — partial conflict [bundle:5] [bundle:28]

References

• Lee 2026. Long-term outcomes in elderly colorectal cancer patients with presarcopenia: a single center retrospective cohort study. BMC Geriatrics, 2026. DOI: 10.1186/s12877-026-06995-w PMID: 41688948.
• Li 2026a. Cancer and the risk of death, heart-failure hospitalization, and major adverse cardiovascular events in HFpEF: a propensity-matched cohort study. Frontiers in Oncology, 2026. DOI: 10.3389/fonc.2026.1728009 PMID: 41768242.
• Sahin 2026. Can the frailty score independently predict postoperative morbidity in patients with colorectal cancer? A prospective observational study. BMC Geriatrics, 2026. DOI: 10.1186/s12877-026-07255-7 PMID: 41761087.
• Jin 2026. Impact of pre-operative frailty on short-term outcomes of ovarian cancer: a systematic review and meta-analysis. Journal of Ovarian Research, 2026. DOI: 10.1186/s13048-026-01982-6 PMID: 41606619.
• Torres 2025. Long-Term Effectiveness of Dietary Interventions on Inflammatory Biomarkers in Women with Breast Cancer: A Systematic Review and Meta-Analysis. Nutrition Reviews, 2025. DOI: 10.1093/nutrit/nuaf137 PMID: 40814965.
• Houdt 2026. A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: the RibOB study. ESMO Open, 2026. DOI: 10.1016/j.esmoop.2025.105896 PMID: 41512682.
• Anker 2025. Heart failure therapy in patients with advanced cancer receiving specialized palliative care (EMPATICC trial). European Heart Journal, 2025. DOI: 10.1093/eurheartj/ehaf705 PMID: 40884070.
• Svendsen 2026. Change in skeletal muscle mass during systemic cancer treatment: a systematic review and meta-analysis. Acta Oncologica, 2026. DOI: 10.2340/1651-226X.2026.45726 PMID: 42200373.
• Hernandez-Garcia 2026. In-bedroom renewed air as anti-inflammatory adjuvant therapy in cancer survivors: protocol for the randomised, placebo-controlled BREATHS N-of-1 trial series. BMJ Open, 2026. DOI: 10.1136/bmjopen-2025-111748 PMID: 42303407.
• Zopf 2026. Exercise effects on lean body mass, muscle strength and functional performance in patients with metastatic breast cancer: the randomized controlled PREFERABLE-EFFECT study. Breast Cancer Research : BCR, 2026. DOI: 10.1186/s13058-026-02235-6 PMID: 41975453.
• Asencio-Mas 2026. Effects of Diet and Exercise Lifestyle Interventions on Physical and Psychological Health in Breast Cancer Survivors: A Systematic Review. Nutrients, 2026. DOI: 10.3390/nu18111815 PMID: 42280460.
• Fujimoto 2025. Impact of diabetes mellitus and grip strength on postoperative outcomes in older patients undergoing cancer surgery: A single‐center retrospective cohort study. Journal of Diabetes Investigation, 2025. DOI: 10.1111/jdi.70224 PMID: 41457653.
• Li 2026b. Impact of Preoperative Frailty on Postoperative Complications and Cognitive Impairment in Liver Cancer Patients: An Observational Cohort Study. Clinical Interventions in Aging, 2026. DOI: 10.2147/CIA.S589717 PMID: 41948538.
• Ruiz-Campos 2026. Grading the evidence on the effects of exercise interventions in children and adolescents during and beyond cancer treatment: an umbrella review of systematic reviews with meta-analyses. British Journal of Sports Medicine, 2026. DOI: 10.1136/bjsports-2025-110756 PMID: 41850726.
• Gao 2026. Association between malnutrition and prognosis in colorectal cancer: a systematic review and meta-analysis. Frontiers in Oncology, 2026. DOI: 10.3389/fonc.2026.1789366 PMID: 42180068.
• Ji 2026. Long-Term Outcomes of Concurrent Chemoradiotherapy With S-1 in Older Patients With Esophageal Cancer. JAMA Network Open, 2026. DOI: 10.1001/jamanetworkopen.2026.3541 PMID: 41893843.
• Gwenzi 2026. Effects of personalized vitamin D 3 on inflammation in colorectal cancer patients: a randomized trial. British Journal of Cancer, 2026. DOI: 10.1038/s41416-025-03333-6 PMID: 41507560.
• Hu 2025. Lobaplatin versus cisplatin in concurrent chemoradiotherapy for elderly cervical cancer: randomized controlled phase II study. Journal of Gynecologic Oncology, 2025. DOI: 10.3802/jgo.2026.37.e33 PMID: 41381401.
• Rajamaki 2026. Age, Age‐Related Comorbidities and Survival in Palbociclib, Ribociclib and Abemaciclib Users With Advanced Breast Cancer: A Nation‐Wide Retrospective Cohort Study. Pharmacoepidemiology and Drug Safety, 2026. DOI: 10.1002/pds.70416 PMID: 42301003.
• Zhang 2026. Intravenous lidocaine reduces systemic inflammation but not myocardial injury following thoracic surgery for lung cancer: a randomized controlled trial. BMC Anesthesiology, 2026. DOI: 10.1186/s12871-026-03733-y PMID: 41794665.
• RamirezGiraldo 2026. Impact of Age on Surgical and Oncologic Outcomes After Colorectal Cancer Resection in Selected Patients Undergoing Primary Anastomosis: A Retrospective Propensity‐Matched Cohort Study. Cancer Medicine, 2026. DOI: 10.1002/cam4.71927 PMID: 42124322.
• Ding 2026. Esketamine-sufentanil PCA reduces postoperative depression state in elderly colorectal cancer patients: a randomized controlled trial. Scientific Reports, 2026. DOI: 10.1038/s41598-026-49287-4 PMID: 42014775.
• Galavotti 2026. Integrating Exercise and Education into Lung Cancer Care: Results from the OVER-CRF Pilot Study on Cancer-Related Fatigue and Quality of Life. Current Oncology, 2026. DOI: 10.3390/curroncol33060313 PMID: 42346213.
• Huang 2026. Dose–response effect of statins on colorectal cancer risk in IBD: a nationwide cohort study. BMC Cancer, 2026. DOI: 10.1186/s12885-026-15970-y PMID: 41963812.
• Yuan 2026. Efficacy and safety of neoadjuvant therapies for high-risk and locally advanced prostate cancer in older adults: a systematic review and network meta-analysis. Frontiers in Oncology, 2026. DOI: 10.3389/fonc.2026.1796138 PMID: 42255215.
• Veenhuizen 2026. Effect of yoga on musculoskeletal complaints in women during endocrine treatment for breast cancer: protocol of the randomised controlled COBRA trial. BMJ Open, 2026. DOI: 10.1136/bmjopen-2026-117251 PMID: 42264518.
• Peker 2026. Impact of prognostic nutritional index and geriatric nutritional risk index on prognosis in elderly patients with early-stage prostate cancer. Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1745718 PMID: 41783818.
• Ahmad 2026. In-hospital outcomes of acute coronary syndrome in patients with cancer: a systematic review and meta-analysis. J Cardiovasc Med (Hagerstown), 2026. DOI: 10.2459/jcm.0000000000001894 PMID: 42378317.
• Matsuoka 2026. Feasibility of a mobile application-based geriatric assessment and communication support intervention for older adults with cancer: protocol for a pilot randomised controlled trial (MAPLE2 pilot). BMJ Open, 2026. DOI: 10.1136/bmjopen-2025-112309 PMID: 41571409.
• Deutschmann 2026. Management of Bone-Only Progressive Disease in Metastatic Breast Cancer—A Retrospective Single-Center Analysis. Journal of Clinical Medicine, 2026. DOI: 10.3390/jcm15093456 PMID: 42123191.
• Nucci 2026. Mediterranean diet in cancer patients' survival: A systematic review and meta-analysis for tertiary prevention featured in the Italian National Guidelines "La Dieta Mediterranea". Nutrition, 2026. DOI: 10.1016/j.nut.2025.113071 PMID: 41579434.
• Noronha 2026. Geriatric Oncology multidomain intervention study to prevent Cognitive impairment among older Indian patients with cancer receiving chemotherapy: a multicentric randomised controlled trial (GOCog). BMC Geriatrics, 2026. DOI: 10.1186/s12877-026-07513-8 PMID: 42034980.
• Marginean 2026. Cardiovascular Vulnerability, Including Heart Failure Risk, in Breast Cancer Surgery: The Role of Operative Technique, Frailty, and Postoperative Complications. Medicina, 2026. DOI: 10.3390/medicina62050877 PMID: 42195130.
• Burgos-Bragado 2026. Asynchronous telerehabilitation in prehabilitation and postoperative recovery for colorectal cancer: A protocol for a randomized controlled trial. PLOS One, 2026. DOI: 10.1371/journal.pone.0333649 PMID: 42060648.
• Normann 2026. “Having surgery is necessary” – a qualitative analysis of the experiences of frail older adults treated with, and recovering from colorectal cancer surgery. BMC Geriatrics, 2026. DOI: 10.1186/s12877-026-07356-3 PMID: 41845272.
• Cui 2026. Comparative efficacy of aerobic exercise and mind-body practices in improving sleep quality and psychological distress among elderly breast cancer patients: a systematic review. Frontiers in Oncology, 2026. DOI: 10.3389/fonc.2026.1798402 PMID: 41959904.
• Pecorelli 2026. Multimodal Prehabilitation In Pancreatic cancer Patients undergoing surgery (PIPS): study protocol for a randomized controlled trial. Trials, 2026. DOI: 10.1186/s13063-026-09467-z PMID: 41618415.
• Carlos 2026. Immune Checkpoint Inhibitors in Elderly Patients With Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Subgroup Evidence. Clin Breast Cancer, 2026. DOI: 10.1016/j.clbc.2026.04.005 PMID: 42168077.
• Orchard 2026. Cancer Incidence and Mortality With Aspirin in Older Adults: Follow-Up of the ASPREE Trial. JAMA Oncol, 2026. DOI: 10.1001/jamaoncol.2025.6196 PMID: 41609798.